Lenalidomide in  treatment of relapsed/refractory nonHodgkin's Bcell lymphoma

doi:10.3969/j.issn.1004-583X.2019.06.005

Clinical Focus

Previous Articles Next Articles

Lenalidomide in treatment of relapsed/refractory nonHodgkin's Bcell lymphoma

1.Department of Hematology, Huai'an First People's Hospital, Nanjing Medical University,
Huai'an 223300, China; 2. Key Laboratory of Hematology of Nanjing Medical University,
Huai'an 223300, China

Online:2019-06-20 Published:2019-08-02
Contact: Corresponding author: Wang Chunling, Email: wcl6506@163.com

Abstract

Abstract: Patients with relapsed/refractory nonHodgkin's lymphoma (R/R NHL) have poor overall prognosis. More and more new drugs and targeted drugs are applied to improve the survival of R/R NHL. Lenalidomide has been used in various subtypes of NHL to improve the therapeutic effect, especially in Bcell lymphoma, due to its immunomodulatory effects, inhibition of angiogenesis and direct antitumor activity. Based on the existing evidence, this review summarizes the application of lenalidomide to R/R NHL.

Key words: lymphoma, nonHodgkin；lenalidomide;prognosis；drug therapy

Bei Liye1, 2, Shi Yuye1, 2, Wang Chunling1, 2. Lenalidomide in treatment of relapsed/refractory nonHodgkin's Bcell lymphoma[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2019.06.005.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2019.06.005

https://huicui.hebmu.edu.cn/EN/Y2019/V34/I6/508

[1]	Liu Lili, Yuan Yuting, Lai Gengliang, Tian Chuan, Lan Xiang, Ye Zhonglv. The relationship between minimal residual disease on day 15 and prognosis in children with acute lymphoblastic leukemia [J]. Clinical Focus, 2024, 39(1): 47-52.
[2]	Yang Wei, He Chendong. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with dry cough as the only symptom: A case and literature review [J]. Clinical Focus, 2023, 38(7): 623-627.
[3]	Du Jiayi, Liu Lili, He Yongzhong, Tian Chuan, Lan Xiang, Ye Zhonglyu. Clinical observation of serious adverse events in children with acute lymphoblastic leukemia during chemotherapy [J]. Clinical Focus, 2023, 38(2): 149-154.
[4]	Mao Rong, Tao Qianshan, Shen Yuanyuan, Dong Yi. A case with extranodal NK/T cell lymphoma-related hemophagocyte syndrome [J]. Clinical Focus, 2022, 37(7): 635-639.
[5]	Lu Luo, Wang Fei, Gu Weiying. Clinical determination of lymphocyte subsets in peripheral blood of patients with angioimmunoblastic T cell lymphoma [J]. Clinical Focus, 2022, 37(11): 1001-1007.
[6]	Yin Lingling, Wu Wenjian, Zhu Feng. Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(11): 1025-1030.
[7]	Shen Rui, Lei Yanhua, Jia Haokun. Analysis of the incidence and risk factors for venous thromboembolism in 145 patients with diffuse large B-cell lymphoma [J]. Clinical Focus, 2022, 37(1): 43-45.
[8]	Cheng Li, Huang Wenrong. Effects of autologous hematopoietic stem cell transplantation in primary central nervous system lymphoma [J]. Clinical Focus, 2021, 36(10): 901-904.
[9]	Mu Xiaohui, Ai Limei. Expression of mirna141 in diffuse large B cell lymphoma and its relationship with prognosis [J]. Clinical Focus, 2020, 35(8): 727-731.
[10]	Yu Yijiao, Du Juan, Li Wei, Cai Yiling, Zhu Lin, Lu Dongxu, Liu Li. Intravascular large Bcell lymphoma with myelopathy as the first manifestation: a case report and literature review [J]. Clinical Focus, 2020, 35(8): 740-744.
[11]	Bian Le, Ai Limei. Expression of apoptosisregulating proteins XIAP and Omi/HtrA2 in diffuse large Bcell lymphoma and relationship with prognosis [J]. Clinical Focus, 2020, 35(5): 438-444.
[12]	Chen Xianrui, Wen Hong, Huang Jianqi, Guo Biyun, Bai Haitao, Wu Jinzhun. Relationship between ARID5B gene rs10821936 polymorphism and risk of childhood acute lymphoblastic leukemia: a systematic and metaanalysis [J]. Clinical Focus, 2020, 35(3): 197-205.
[13]	Yu Yuehua， Zhao Dehao. Subacute primary Bcell lymphoma of primary central nervous system with symmetrical lesions: a case report and literature review [J]. Clinical Focus, 2019, 34(7): 664-667.
[14]	Wang Fei, Yue Yanhua, Lu Luo, Gu Weiying. Diagnosis and treatment of primary central nervous system lymphoma [J]. Clinical Focus, 2019, 34(6): 502-507.
[15]	Huang Shanshan, Niu Yang, Wu Jiang. The role of body composition indicators in evaluating the treatment and prognosis of patients with lymphoma [J]. Clinical Focus, 2019, 34(6): 496-501.

Lenalidomide in treatment of relapsed/refractory nonHodgkin's Bcell lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments